Logo image of ONC

BEIGENE LTD-ADR (ONC) Stock Fundamental Analysis

NASDAQ:ONC - Nasdaq - US07725L1026 - ADR - Currency: USD

236.86  +3.49 (+1.5%)

After market: 236.86 0 (0%)

Fundamental Rating

4

ONC gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. Both the profitability and financial health of ONC have multiple concerns. ONC is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

ONC had positive earnings in the past year.
In the past year ONC has reported a negative cash flow from operations.
ONC had negative earnings in each of the past 5 years.
ONC had a negative operating cash flow in each of the past 5 years.
ONC Yearly Net Income VS EBIT VS OCF VS FCFONC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -2B -4B -6B -8B -10B

1.2 Ratios

ONC's Return On Assets of -11.62% is amongst the best of the industry. ONC outperforms 84.85% of its industry peers.
ONC has a better Return On Equity (-20.59%) than 85.74% of its industry peers.
Industry RankSector Rank
ROA -11.62%
ROE -20.59%
ROIC N/A
ROA(3y)-19.6%
ROA(5y)-21.52%
ROE(3y)-30.77%
ROE(5y)-32.33%
ROIC(3y)N/A
ROIC(5y)N/A
ONC Yearly ROA, ROE, ROICONC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Gross Margin of ONC (83.97%) is better than 87.17% of its industry peers.
In the last couple of years the Gross Margin of ONC has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for ONC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y0.23%
ONC Yearly Profit, Operating, Gross MarginsONC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

3

2. Health

2.1 Basic Checks

ONC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ONC has been increased compared to 1 year ago.
The number of shares outstanding for ONC has been increased compared to 5 years ago.
Compared to 1 year ago, ONC has a worse debt to assets ratio.
ONC Yearly Shares OutstandingONC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ONC Yearly Total Debt VS Total AssetsONC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B 50B

2.2 Solvency

An Altman-Z score of 4.46 indicates that ONC is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 4.46, ONC is doing good in the industry, outperforming 79.14% of the companies in the same industry.
ONC has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ONC (0.31) is worse than 72.19% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z 4.46
ROIC/WACCN/A
WACC9.84%
ONC Yearly LT Debt VS Equity VS FCFONC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10B -10B 20B 30B

2.3 Liquidity

A Current Ratio of 1.81 indicates that ONC should not have too much problems paying its short term obligations.
With a Current ratio value of 1.81, ONC is not doing good in the industry: 78.25% of the companies in the same industry are doing better.
A Quick Ratio of 1.58 indicates that ONC should not have too much problems paying its short term obligations.
ONC has a worse Quick ratio (1.58) than 80.04% of its industry peers.
Industry RankSector Rank
Current Ratio 1.81
Quick Ratio 1.58
ONC Yearly Current Assets VS Current LiabilitesONC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

More info and screens

7

3. Growth

3.1 Past

ONC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 211.65%, which is quite impressive.
The Revenue has grown by 56.19% in the past year. This is a very strong growth!
ONC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 55.91% yearly.
EPS 1Y (TTM)211.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150.9%
Revenue 1Y (TTM)56.19%
Revenue growth 3Y53.06%
Revenue growth 5Y55.91%
Sales Q2Q%50.65%

3.2 Future

ONC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 102.66% yearly.
Based on estimates for the next years, ONC will show a quite strong growth in Revenue. The Revenue will grow by 18.74% on average per year.
EPS Next Y109.55%
EPS Next 2Y64.57%
EPS Next 3Y50.96%
EPS Next 5Y102.66%
Revenue Next Year37.61%
Revenue Next 2Y28.01%
Revenue Next 3Y23.14%
Revenue Next 5Y18.74%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ONC Yearly Revenue VS EstimatesONC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20B 40B 60B
ONC Yearly EPS VS EstimatesONC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 500 1K 1.5K 2K 2.5K

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 5.89, which indicates a rather cheap valuation of ONC.
Based on the Price/Earnings ratio, ONC is valued cheaply inside the industry as 98.40% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.60, ONC is valued rather cheaply.
ONC is valuated quite expensively with a Price/Forward Earnings ratio of 51.39.
ONC's Price/Forward Earnings ratio is rather cheap when compared to the industry. ONC is cheaper than 89.48% of the companies in the same industry.
ONC is valuated expensively when we compare the Price/Forward Earnings ratio to 22.43, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 5.89
Fwd PE 51.39
ONC Price Earnings VS Forward Price EarningsONC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONC Per share dataONC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

ONC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ONC's earnings are expected to grow with 50.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.05
PEG (5Y)N/A
EPS Next 2Y64.57%
EPS Next 3Y50.96%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ONC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEIGENE LTD-ADR

NASDAQ:ONC (5/20/2025, 8:25:00 PM)

After market: 236.86 0 (0%)

236.86

+3.49 (+1.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)08-05 2025-08-05
Inst Owners26.4%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change0%
Market Cap25.53B
Analysts81.67
Price Target258.74 (9.24%)
Short Float %26.08%
Short Ratio3.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.5
Dividend Growth(5Y)N/A
DP-7.66%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)888.88%
Min EPS beat(2)-22.81%
Max EPS beat(2)1800.57%
EPS beat(4)1
Avg EPS beat(4)-6.86%
Min EPS beat(4)-999.2%
Max EPS beat(4)1800.57%
EPS beat(8)2
Avg EPS beat(8)-1.88%
EPS beat(12)3
Avg EPS beat(12)-17.16%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)2.88%
Min Revenue beat(2)0.26%
Max Revenue beat(2)5.5%
Revenue beat(4)4
Avg Revenue beat(4)12.85%
Min Revenue beat(4)0.26%
Max Revenue beat(4)28.03%
Revenue beat(8)8
Avg Revenue beat(8)16.8%
Revenue beat(12)12
Avg Revenue beat(12)14.33%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.04%
PT rev (3m)N/A
EPS NQ rev (1m)-1.64%
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.64%
EPS NY rev (3m)339.54%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)1.35%
Revenue NY rev (3m)10.59%
Valuation
Industry RankSector Rank
PE 5.89
Fwd PE 51.39
P/S 6.77
P/FCF N/A
P/OCF N/A
P/B 7.62
P/tB 8
EV/EBITDA N/A
EPS(TTM)40.2
EY16.97%
EPS(NY)4.61
Fwd EY1.95%
FCF(TTM)-6.02
FCFYN/A
OCF(TTM)-1.62
OCFYN/A
SpS35.01
BVpS31.1
TBVpS29.6
PEG (NY)0.05
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.62%
ROE -20.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.97%
FCFM N/A
ROA(3y)-19.6%
ROA(5y)-21.52%
ROE(3y)-30.77%
ROE(5y)-32.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y0.23%
F-Score4
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 12.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.81
Quick Ratio 1.58
Altman-Z 4.46
F-Score4
WACC9.84%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)20.18%
Cap/Sales(5y)27.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)211.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150.9%
EPS Next Y109.55%
EPS Next 2Y64.57%
EPS Next 3Y50.96%
EPS Next 5Y102.66%
Revenue 1Y (TTM)56.19%
Revenue growth 3Y53.06%
Revenue growth 5Y55.91%
Sales Q2Q%50.65%
Revenue Next Year37.61%
Revenue Next 2Y28.01%
Revenue Next 3Y23.14%
Revenue Next 5Y18.74%
EBIT growth 1Y51.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year145.3%
EBIT Next 3Y67.5%
EBIT Next 5Y57.12%
FCF growth 1Y60.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y83.84%
OCF growth 3YN/A
OCF growth 5YN/A